{"id":765,"date":"2021-01-14T08:55:03","date_gmt":"2021-01-14T08:55:03","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=765"},"modified":"2021-01-14T08:55:03","modified_gmt":"2021-01-14T08:55:03","slug":"07-jan-2021-ruxolitinib-was-associated-with-significant-reduction-of-biomarkers-of-inflammation","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/07-jan-2021-ruxolitinib-was-associated-with-significant-reduction-of-biomarkers-of-inflammation\/","title":{"rendered":"(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Compassionate use of Ruxolitinib in patients with SarsCov-2 infection not on mechanical ventilation. Short-term effects on inflammation and ventilation<\/p>\n<p>https:\/\/doi.org\/10.1111\/cts.12971<\/p>\n<p class=\"\">Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for Sars-CoV-2 infection. Inclusion criteria were oxygen saturation &lt;\/= 92%, signs of interstitial pneumoniae, and no need of mechanical ventilation. Patients received 5 mg bid of ruxolitinib for 15 days, data were collected at baseline and at day 4, 7 and 15 during treatment. Two main targets were identified, C-reactive protein (CRP) and PaO2\/FiO2 ratio. In the 31 patients who received ruxolitinib symptoms improved (dyspnea scale) at day 7 in 25 out of 31 patients (80.6%); C-reactive protein decreased progressively from baseline (79.1+\/-73.4 mg\/dl) to day15 (18.6+\/-33.2, p=0.022). In parallel with CRP, PO2\/FiO2 ratio increased progressively during the three steps from 183+\/-95 to 361+\/-144 mmHg (p &lt; 0.001). In those patients with a reduction of PCR &lt;\/= 80%, delta increase of the PO2\/FiO2 ratio was significantly more pronounced (129+\/-118 vs 45+\/-35 mmHg, p=0.02). No adverse side effects were recorded during treatment. In patients hospitalized for Covid 19 compassionate-use of ruxolitinib determined a significant reduction of biomarkers of inflammation which was associated with a more effective ventilation and reduced need for oxygen support. Data on ruxolitinib reinforces the hypothesis that targeting hyperinflammation state, may be of prognostic benefit in patients with Sars-Covid-2 infection.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compassionate use of Ruxolitinib in patients with SarsCov-2 infection not on mechanical ventilation. Short-term effects on inflammation and ventilation https:\/\/doi.org\/10.1111\/cts.12971 Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for Sars-CoV-2 infection. Inclusion criteria were&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/07-jan-2021-ruxolitinib-was-associated-with-significant-reduction-of-biomarkers-of-inflammation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,66],"tags":[67],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/765"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=765"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/765\/revisions"}],"predecessor-version":[{"id":766,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/765\/revisions\/766"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}